Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
A Phase IV Master Protocol of Cosibelimab in Special Populations With Advanced Cutaneous Squamous Cell Carcinoma (CosiMaster)
Dana-Farber Cancer Institute
80 participants
Apr 23, 2026
INTERVENTIONAL
Conditions
Summary
This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Anti-PD-L1 antibody, single dose vials, via intravenous (into the vein) infusion per protocol
Corticosteroid, per standard of care
mTOR Inhibitor, per standard of care
mTOR Inhibitor, per standard of care
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07426484